Dosing has begun in LIGHTHOUSE, a Phase 3 clinical trial testing BIIB122 — an experimental inhibitor of LRRK2 being developed by Biogen and Denali Therapeutics — in patients with early-stage Parkinson’s disease. The study (NCT05418673), underway at two clinical sites in Colorado and Florida, is recruiting up…
A research team at the Icahn School of Medicine at Mount Sinai, New York has won the 2022 Parkinson’s Foundation Research Center Award, valued at $2 million, to study the process that results in the selective loss of dopaminergic neurons in Parkinson’s disease. The team, led by…
The pharmaceutical company Kyowa Kirin has unveiled an effort to help educate Parkinson’s disease patients and healthcare professionals about “off” episodes and treatments such as Nourianz (istradefylline), an adjunctive therapy it developed for such times. The new resources ultimately seek to empower adult patients to discuss “off” times…
CENTOGENE has announced it’s reached a milestone of 12,500 participants who have been recruited and genetically tested as part of the Rockstock International Parkinson’s Disease Study (ROPAD), a global observational effort to characterize the genetic profile of Parkinson’s patients. ROPAD (NCT03866603), developed in collaboration with Denali…
Older age at onset, more severe motor symptoms, and cognitive impairment are risk factors for the progression of gait and postural instability in Parkinson’s disease patients who undergo deep brain stimulation, a new study suggests. Researchers, who followed patients for up to 15 years after the surgery, found…
Free art therapy workshops for Parkinson’s disease patients and their caregivers will take place this fall in Little Rock and Hot Springs, Arkansas, offered by the University of Arkansas for Medical Sciences (UAMS) Movement Disorders Clinic. The Art for Parkinson’s classes are scheduled in Little Rock at St. Michael’s…
Ventus Therapeutics and Novo Nordisk have agreed to work together to develop new anti-inflammatory medicines that may be useful in Parkinson’s disease and other disorders, the companies announced. “This is an important collaboration for Ventus that validates our structural biology capabilities to discover and develop highly differentiated…
People with Parkinson’s disease who underwent acupuncture for eight weeks had significantly lower levels of anxiety at a follow-up visit two months later than those who received a sham procedure, a clinical trial from China reported. Trial findings also suggested that acupuncture may be an effective way to improve…
Parkinson’s patients with a postural abnormality called Pisa syndrome show deficits in their ability to process visual and balance-related information, a new study done using virtual reality suggests. “The visual tilting perception assessed in our study is a visual domain task, and our study revealed that [Pisa syndrome]…
Poor sleep quality is a key factor in developing dyskinesia, the uncontrolled and involuntary movements that can affect people with Parkinson’s disease, a study that followed patients for up to three years suggests. “[Poor sleep quality] may increase the risk of developing dyskinesia in PD [Parkinson’s disease], implying that therapeutic…
Get regular updates to your inbox.
